# Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies

> **NCT00990717** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 8 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Myeloma
- Hodgkin's Disease

## Interventions

- **BIOLOGICAL:** NK-92 cells

## Key facts

- **NCT ID:** NCT00990717
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2012-07
- **Final completion:** 2012-07
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2016-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00990717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00990717, "Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00990717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*